Hypoxemic Respiratory Failure Clinical Trial
Official title:
Impact of High-level Oxygen Therapy on the Reconditioning of Type I Hypoxemic Respiratory Insufficiency Patients in Intensive Care
Verified date | March 2022 |
Source | Brugmann University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
High-throughput oxygen therapy is known as an alternative to non-invasive ventilation, with a benefit in terms of survival in non-hypercapnic respiratory failure patients. The use of high-throughput oxygen therapy is well studied in stable chronic obstructive pulmonary disease (COPD) patients and has as known effects the decrease of transcutaneous CO2 and respiratory rate, and the increase in the inspiratory/expiratory time report, in the tidal volume and in the forced expiratory volume per second. In the event of an exacerbation, high-flow oxygen therapy has shown to be beneficial in terms of increased mean airway pressure, tidal volume with a decrease in hypercapnia, and respiratory rate. The net effect on the CO2 pressure is linked to the CO2 clearance of the dead anatomical space by the high throughput. The effect can be compared with the one of non invasive ventilation in a stable COPD patient. Oxygen therapy, even in patients with non-hypoxic COPD at rest, has benefits in terms of performance and improvement of quality of life. High-throughput oxygen therapy has also shown a benefit in COPD patients in revalidation units, in terms of exercise performance and oxygenation. However, the reconditioning of critical patients in acute situations, by means of nasal goggles, has never been studied.
Status | Completed |
Enrollment | 30 |
Est. completion date | August 3, 2020 |
Est. primary completion date | August 3, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Acute respiratory insufficiency type I, oxygen partial pressure (PaO2) <60 mmHg under oxygen without hypercapnia. - Invasive arterial pressure measure Exclusion Criteria: - Hemodynamic instability - Patient under continuous high throughput oxygen therapy - Left cardiac insufficiency - Arteritis of the lower limbs - Neuromuscular pathology - Osteo-articular limitations - Hemoglobin inferior to 8g/dl |
Country | Name | City | State |
---|---|---|---|
Belgium | CHU Brugmann | Brussels |
Lead Sponsor | Collaborator |
---|---|
Dr David DE BELS |
Belgium,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Pulsated oxygen saturation (Sp02) | SpO2 is an estimate of the amount of oxygen in the blood. More precisely, it represents the percentage of oxygenated hemoglobin (containing oxygen) relative to the total amount of hemoglobin in the blood (oxygenated hemoglobin and non-oxygenated hemoglobin). | Baseline | |
Primary | Pulsated oxygen saturation (Sp02) | SpO2 is an estimate of the amount of oxygen in the blood. More precisely, it represents the percentage of oxygenated hemoglobin (containing oxygen) relative to the total amount of hemoglobin in the blood (oxygenated hemoglobin and non-oxygenated hemoglobin). | 12 minutes (maximal effort) | |
Primary | Oxygen inspired fraction (FiO2) | Oxygen inspired fraction (FiO2) is the fraction or percentage of oxygen present in the gas mixture that a person breathes. | Baseline | |
Primary | Oxygen inspired fraction (FiO2) | Oxygen inspired fraction (FiO2) is the fraction or percentage of oxygen present in the gas mixture that a person breathes. | 12 minutes (maximal effort) | |
Primary | Blood gasometry | Arterial blood analysis | Baseline | |
Primary | Blood gasometry | Arterial blood analysis | 12 minutes (maximal effort) | |
Primary | Heart rate | The heart rate is the number of heartbeats per unit minute. | Baseline | |
Primary | Heart rate | The heart rate is the number of heartbeats per minute. | 12 minutes (maximal effort) | |
Primary | Respiratory rate | Number of breath cycles (inspiration and expiration) per minute. | Baseline | |
Primary | Respiratory rate | Number of breath cycles (inspiration and expiration) per minute. | 12 minutes (maximal effort) | |
Primary | Mean arterial pressure | Mean arterial pressure | Baseline | |
Primary | Mean arterial pressure | Mean arterial pressure | 12 minutes (maximal effort) | |
Primary | Systolic blood pressure | Systolic blood pressure (pressure in the artery as the heart contracts) | Baseline | |
Primary | Systolic blood pressure | Systolic blood pressure (pressure in the artery as the heart contracts) | 12 minutes (maximal effort) | |
Primary | Borg score | The Borg scale is a quantitative measure of the perception of effort during exercise. The scale between 0 and 10 was designed to approximate the heart rate of a healthy young adult (effort 8 represents 80% of the cardiac frequency). | 12 minutes (maximal effort) | |
Primary | Forced expiratory volume per second (FEV1) | The "Forced Expiratory Volume Per Second" (FEV1) is the volume of air exhaled during the first second of a so-called "forced" exhalation, following deep inspiration. It is measured by spirometry. | Baseline | |
Primary | Functional residual capacity (CFR) | Volume of air remaining in the airways after a spontaneous expiration (not forced) | Baseline | |
Secondary | Age | Age | Baseline | |
Secondary | Weight | Weight | Baseline | |
Secondary | Sex | Sex | Baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|
||
Completed |
NCT04357457 -
Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia
|
Phase 3 | |
Completed |
NCT04982341 -
HFNC and Prone Positioning in Awake Patients With Severe COVID-19
|
||
Recruiting |
NCT05880836 -
In Line Aerosol Nebulization With High Flow
|
N/A | |
Completed |
NCT04934163 -
Flow Rates of High-flow Nasal Cannula and Extubation Outcome
|
N/A | |
Completed |
NCT03282552 -
High Flow Oxygen Therapy Versus Conventional Oxygen Therapy in Cardiac Surgery Patients
|
N/A | |
Recruiting |
NCT04079465 -
Automated Oxygen Control by O2matic to Patients Admitted With Acute Hypoxemia
|
N/A | |
Recruiting |
NCT05363332 -
Impact and Sequelae of High Ventilatory Drive in Critically Ill COVID-19 Patients
|
||
Active, not recruiting |
NCT05155202 -
Clinical Relevance of Nicardipine Induced Hypoxemia in the Intensive Care Unit
|
||
Withdrawn |
NCT04381923 -
COVIDNOCHE Trial (HFNO Versus CPAP Helmet) in COVID-19 Pneumonia
|
N/A | |
Recruiting |
NCT04402879 -
CORONA (COvid pRONe hypoxemiA): Prone Positioning for Hypoxemic COVID-19 Patients With Do-not-intubate Goals
|
N/A | |
Not yet recruiting |
NCT06064409 -
Optimal Timing and Failure Prediction of High Flow Nasal Cannula Oxygen Therapy in Emergency Department: Prospective Observational Single Center Study
|
||
Completed |
NCT04445246 -
Inhaled Iloprost for Suspected COVID-19 Respiratory Failure
|
Phase 2 | |
Completed |
NCT03438383 -
Bi-PAP vs Sham Bi-PAP on Pulmonary Function in Morbidly Obese Patients After Bariatric Surgery
|
N/A | |
Completed |
NCT04694638 -
Use of Combined Prone Positioning and High-Flow Nasal Cannula, and Non-invasive Positive Pressure Ventilation to Prevent Intubation in COVID-19 Infection
|
N/A | |
Completed |
NCT04853979 -
Awake Prone Positioning in COVID-19 Suspects With Hypoxemic Respiratory Failure
|
N/A | |
Recruiting |
NCT05089695 -
Helmet NIV vs. CPAP vs. High-flow Nasal Oxygen in Hypoxemic Respiratory Failure
|
N/A | |
Completed |
NCT05124197 -
Extended Prone Position Duration COVID-19-related ARDS: a Retrospective Study
|
||
Completed |
NCT03589482 -
Assessing Lung Inhomogeneity During Ventilation for Acute Hypoxemic Respiratory Failure
|
N/A | |
Completed |
NCT03174002 -
Handling Oxygenation Targets in the Intensive Care Unit
|
Phase 4 |